Topics

Leukotriene A 4 Hydrolase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

21:10 EST 12 Feb 2020 | BioPortfolio Reports

Leukotriene A 4 Hydrolase Pipeline Review, H2 2019


Summary


Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukotriene A 4 Hydrolase Pipeline Review, H2 2019, outlays comprehensive information on the Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 Leukotriene A4 hydrolase LTA4H is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAFinduced shock. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Respiratory, Immunology, Cardiovascular and Dermatology which include indications Inflammation, Chronic Obstructive Pulmonary Disease COPD, Cystic Fibrosis, Emphysema, Primary Ciliary Dyskinesia and Pulmonary Arterial Hypertension.


Furthermore, this report also reviews key players involved in Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Scope


The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6

The report reviews Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics and enlists all their major and minor projects

The report assesses Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Leukotriene A 4 Hydrolase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Leukotriene A 4 Hydrolase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...